Raloxifene HCl belongs to a class of selective estrogen receptor modulators (SERMs) which is used for the management of breast cancer. The major problem reported with raloxifene is its poor bioavailability which is only up to 2%. The main objective of the present work was to formulate raloxifene loaded ethosomal preparation for transdermal application and compare it with an oral formulation of the drug. Five ethosomal formulations with different concentrations of ethanol and a conventional liposomes formulation were prepared by rotary evaporation method. The prepared systems were characterised by high resolution transmission electron microscopy (HRTEM), force emission electron microscopy (FESEM), atomic force microscopy (AFM), X-ray diffraction (XRD) and 31 P NMR study. All these advanced characterization study established that the ethosome formulation was well defined by its size, shape and its bilayer formation. Transdermal flux of the optimized ethosome formulation was 22.14 ± 0.83 µg/ml/cm 2 which was 21 times higher when compared to the conventional liposomes. Confocal microscopy study revealed an enhanced permeation of coumarin-6 dye loaded ethosomes to much deeper layers of skin when compared with conventional liposomes. The gel was found to be pseudoplastic with elastic behaviour. In-vivo studies on rats showed a higher bioavailability of RXL (157% times) for ethosomal formulation when compared with the oral formulation. In conclusion, RXL loaded ethosomal formulation via transdermal route showed superior drug delivery properties as compared to oral formulation.
Introduction
Hormone replacement therapy (HRT) is routinely used in treating the osteoporosis and deficiency of bone mineral destiny (BMD) pertaining to bone related disorders (Huang et al., 2013) . HRT incurs a lot of adverse effects to cardiovascular system and poses a chance of breast cancer to postmenopausal women. To address the complication associated with HRT, raloxifene HCl (RXL), a new class of selective estrogen receptor modulator (SERM), has been introduced after the success of Multiple Outcomes of Raloxifene Evaluation (MORE) trial (Ettinger et al., 1999; Palacios et al., 2015) . RXL reduces the possibility of invasive breast cancer to the postmenopausal women (Cuzick et al., 2013; Kanis et al., 2013; Vogel et al., 2006) . RXL treatment produces an antiestrogenic action on the uterus and breast and gives estrogenic effects on the bone and lipid metabolism (Urano et al., 2017) . It is a BCS II class drug with low solubility and high permeability. It undergoes an extensive metabolism and only 2% of the administered drug is utilized in offering therapeutic action. It would be beneficial to deliver RXL through alternative route like transdermal route in order to enhance its poor bioavailability.
The stratum corneum (SC) is notoriously known for their barrier property that limits the primary permeation of a significant number of drugs through the skin. Many novel approaches have been introduced in transdermal drug delivery system to overcome the SC barrier properties, lipid based delivery system is one of them. The first potential use of the lipid based delivery system was reported by Mezei and Gulasekharam (1980) in the form of liposomes (Mezei and Gulasekharam, 1980) . Since then, a constant development in this field has resulted lipid based drug delivery system as a preferred delivery platform for many drug molecules facing issues like bioavailability, solubility, continuous dosing and many others. Lipid vesicles have gained further attention since the introduction of transfersomes by Cevc and Blume (1992) . Transfersomes are flexible, elastic and self-optimised vesicles which are known for permeating through stratum corneum (SC) (Ahmed et al., 2016) . The elasticity feature in transfersomes arises from the use of edge activator that fluidises the lipid bilayer https://doi.org/10.1016/j.ijpharm.2018.02.044 Received 16 December 2017; Received in revised form 16 February 2018; Accepted 27 February 2018 structure of the vesicular structure (Cevc, 2004) . These vesicles are known to entrap and deliver a versatile range of drug molecules like insulin (Agrawal et al., 2013) , antibiotics (ciprofloxacin) (Al-Mahallawi et al., 2017) , carvedilol (Aboud et al., 2016) and many more. Further research on this field has led to the invention of another flexible lipid based carrier system called as ethosomes (Khan and Wong, 2016) . Ethosomal drugs delivery system was developed using lipid (biocompatible component) as a backbone with the addition of 20-50% of ethanol for imparting flexibility in order to penetrate the deeper layers into the skin (Abdel Messih et al., 2017; Mohammed et al., 2016; Paolino et al., 2005; Yan et al., 2016; Zhang et al., 2014) .
In this research, we aim to develop RXL loaded ethosomes for the transdermal delivery of the drug to address its poor bioavailability issue. The developed optimized ethosomal formulation of RXL was compared against an oral formulation in vivo on animal model. An advanced and extensive characterization like microscopy, 31 P NMR, XRD and rheology were done to establish our claim. Conventional liposomes and hydroethanolic RXL solution system were also used for the comparison against prepared RXL loaded ethosomes.
Materials and methods

Materials
Phosphatidylcholine from soybean lecithin Phospholipon® 90G (PC-90G) was purchased from Lipoid GmbH, Nattermannallee, Switzerland. Raloxifene HCl (RXL) was purchased from Binzhou Neophar Pharmaceutical Co. Ltd, China. Coumarin-6 and carbopol® 934 were supplied by Sigma-Aldrich (Ṡt. Louis, MO, USA) and Acros Organic Chemical Co. Ltd. (New Jersey, USA), respectively. Chloroform, methanol, absolute ethanol, calcium chloride and HPLC grade chemicals such as acetonitrile and methanol were purchased from Fisher Scientific Inc. (Malaysia). Highest Grade VI mica covers slip of 20 mm diameter was purchased from AC Scientific Sdn. Bhd. (Malaysia). Orthophosphoric acid, sodium chloride, ammonium hydroxide, calcium-chloride, potassium dihydrogen phosphate, potassium nitrite and dihydrogen sodium phosphate were purchased from Merck Sdn. Bhd. (Malaysia). Nylon and Cellulose acetate membrane of 0.45 µm and 0.22 µm (Titan3) were purchased from Thermo scientific (Malaysia). All other reagents of AR grade were used in this research. Ultrapure distilled water was used during all the experimental work.
Preparation of nanoethosomal formulations
RXL loaded ethosomal system (RES) were prepared using rotary evaporation method as reported in the literature (Jain et al., 2015; Maestrelli et al., 2009 ). Briefly, a calculated amount of Phospholipon® 90G (PC-90G) and RXL were dissolved in a mixture of organic solvent containing methanol and chloroform (1:2, v/v) in a 250 ml dry and clean round-bottom flask. The mixture of the organic solvent was removed by a rotary evaporator (V-205, Buchi Rotavapor, Germany) under reduced pressure of 300 ATM at 43°C and 70 rpm. After the solvent evaporation, a thin uniform layer of PC-90G with RXL was obtained, kept it overnight in vacuum to make it completely dry from any organic solvent traces. Next day, the dried film was hydrated with the mixture of various concentrations of ethanol in double distilled water (20%-45% v/v) using orbital shaker at 100-120 rpm for 1 h at room temperature. The formulation was kept for swelling for 2-3 h at room temperature and the multilamellar vesicles (MLVs) were obtained. To reduce further the size of the vesicles, MLVs were passed through a sandwich membrane of 0.45 µm and 0.22 µm (Titan3) for two times to get the uniform population of the ethosomal vesicles. Prepared formulations together with the concentration of ethanol are given in Table 1 . A conventional liposome formulation loaded with RXL was also prepared using 350 mg PC-90G, 77 mg of cholesterol and 15 mg of RXL. For the confocal laser scanning microscopy (CLSM) study, the optimised ethosomal system and conventional liposome were loaded with 0.003% w/v 6-coumarin dye and used in the study.
Vesicles size, size distribution and zeta potential
Vesicles size and size distribution of the ethosomal system were measured using dynamic light scattering (DLS) technique while laser doppler velocimetry (LDV) was used for zeta-potential measurement. The instrument used for these measurements was Zetasizer Nano ZS (Malvern instrument, U.K) with disposal cuvette for size and cuvette DTS-1060 for zeta-potential. The measurements were performed at temperature 25 ± 0.5°C with 173°fixed scattering angle. Double-distilled and deionized water was used through the measurement to avoid any kind of charge fluctuation and multi-scattering. All measurements were carried out in triplicates (n = 3).
HPLC method
The concentration raloxifene was quantified by HPLC. A reported method (Saini et al., 2012 ) was adopted with a little modification of the chromatographic parameters. The system consisted of Shimadzu LC-20AT low-pressure gradient solvent delivery module, UV detector (SPD-M20A) at 285 nm, and LC workstation data processor (Shimadzu, Kyoto, Japan). A thermo-fisher syncronis C-18 column with 150 × 4.6 mm diameter and 5 μm particle size was used for the elution. A mobile phase, mixture of ACN and pH 3.0 potassium buffer solution (33/67, v/v) , was delivered at a flow rate of 1.0 ml.min −1 isocratically. The linearity was measured within a range of 125 ng/ml to 10 µg/ml. The retention time of RXL was found to be 5.627 min.
Entrapment efficiency (EE %)
EE % of the ethosomal formulations were determined by indirect method as described by Abdel Messih et al. (2017) . Ethosomal formulations were centrifuged (Hanil, Supra 22 K centrifuge with Rotor A50S-8 No.7) at 20,000 rpm and 4°C temperature for 40 min to separate out the unentrapped drug from the vesicles. The vesicles were washed with double distilled water to remove any unentrapped drug attached on the surface of the vesicles. The final supernatant liquid, after an appropriate dilution, was analysed by the HPLC method to quantify RXL. Drug entrapment efficiency was measured by the following equation:
where, E 1 : initial amount of drug, E 2 : quantified drug in the supernatant, and E 1 -E 2 : entrapped drug in the formulation.
Ex-vivo permeation studies
Ex-vivo drug release and permeation studies were conducted by locally fabricated Franz diffusion cell designed to achieve non-occlusive condition. The receptor volume and permeation area were 11 ml and 1.50 cm 2 , respectively. Rat abdominal skin was used as a permeation barrier. The receptor chamber was filled with a mixture of ethanol and PBS 7.4 at a ratio 40:60 (v/v) maintained at 37 ± 1°C and a stirring rate of 100 rpm. On the day of the experiment, skin samples were thawed at room temperature. Before starting the experiment, skin samples were equilibrated for 30 min at 0.9% NaCl solution. The skin was placed over the Franz cell in such a manner that the stratum corneum faced the donor compartment while dermis layer faced the receptor compartment. The skin samples used for the permeation studies were carefully viewed to ensure for any irregularity or damage such as cervices or tiny shacks. A transdermal dose containing 1.2 mg of RXL was used which is also a transdermal therapeutic dose (T d ) of RXL (Mittal et al., 2008) . A sample of volume 0.2 ml was withdrawn at 0, 2, 4, and 6 h from the sample port of the Franz diffusion cell. The receptor was immediately replenished with an equal volume of fresh medium. The skin used in the study was further washed with distilled water, cut into small pieces and sonicated for 30 min followed by high-speed centrifugation to extract out any deposited RXL. The total amount of drug transported via skin by ex-vivo study was calculated as the sum of skin permeation and skin deposition. The permeation was reported as transdermal flux (J, µg/ml/cm 2 ) (Mohammed et al., 2016) . The extent of enhancement of sample against the control was calculated as follows:
=
Enhancement ratio
Steady state flux of formulation Steady state flux of control (2) 2.7. Drug-excipient compatibility study Drug-excipient compatibility was carried out by attenuated total reflectance (ATR) spectroscopy. Individual sample of PC-90G, RXL, physical mixture of PC-90G and RXL and the final optimised formulation of ethosomes in a freeze-dried form were scanned for spectral observations. A total no. of sixteen scans within a scanning range of 400 cm −1 to 4000 cm −1 were performed with Perkin Elmer spectrum two UATR (Llantrisant, U.K).
Differential scanning calorimetry (DSC) study
DSC study was performed to investigate the physical state of drug and lipid when entrapped within the ethosomal vesicles. The evaluation was carried out by Mettler Toledo DSC-1 instrument (LLC Columbus, OH, USA) equipped with Thermo Scientific EK90 Chiller. The samples were sealed into an alumina pan of 40 µl and a blank alumina was used as the reference. The system was supplied with a constant flow of nitrogen gas for the inert environment. A temperature range between −15°C and 300°C was selected for thermal scanning of the samples at two different heating rates like 10°C/min for RXL and 2°C/min for ethosomes and PC-90G.
X-Rays diffraction (XRD) study
Ethosomal formulations were subjected to XRD study to investigate the amorphous phase of the drug within the formulations. RXL was analysed in the powder form, whereas PC-90G, physical mixture of PC-90G and RXL, and ethosomes formulations were analysed in freezedried formed by X-Ray Diffractometer (Rigaku Ultima IV, Tokyo, Japan). Samples were studied by CuKα radiation (40 kV and 40 mA) at the scanning rate of 3°per min over a scanning range 2θ of 3-90°( WAXS, wide angle X-rays scattering) through scintillation counter. The crystal and amorphous behaviour were observed based on the sharpness of the appeared peaks.
Surface morphology, shape and topological measurement
Shape and surface morphology of the ethosomes were visualised by force emission scanning electron microscopy (FESEM), high resolution transmission electron microscopy (HRTEM) whereas topology was investigated by atomic force microscopy (AFM). FESEM measurement was performed with a glass cover slip adhered to the metallic stub by a double-sided tape. A drop of ethosome suspension was completely dried in an oven and coated with platinum by 208HR High Resolution Sputter Coater and visualised by FESEM (JÉOL JSM-7800F, Akishima, Japan). HRTEM analysis was carried out after placing a drop of ethosomes sample on the copper film coated grid, with a diameter of 3.05 mm and 400 mesh size (Ted Pella, PELCO® 400 Mesh Grids). The negative staining was performed using 1% (w/v) phosphotungstic acid solution followed by air drying for 30 min and visualization by Tecnai G2 20S, FEI, Netherland HRTEM instrument. Topology and height analysis of the ethosomes vesicles system were carried out by AFM. A muscovite mica coverslip was used in the analysis. It was cleaned by deionised water and treated to clean any further impurity after heating in an oven at 60°C overnight. A drop of ethosomal formulation was diluted with deionized water in the ratio of 50:1 (v/v), placed on the mica coverslip and scanned after 10 min. The scanning was performed with Bruker BioScope Catalyst AFM (Santa Barbara, USA) with Nasoscope V controller. Tapping mode was used in scanning with ScanAsyst-AIR. Silicon nitride (Si 3 N 4 ) cantilever and pyramidal tips were used for the analysis. The cantilever was having a length of 115-μm with a spring constant (stiffness) of 0.5 N/m with a resonating frequency of 70 kHz. The Radius of curvature of the tip was 0.5 nm with half angle 18°and the stiffness of 0.5 N/m. The sample was scan at 0.501 Hz, with a peak force frequency of 0.5 kHz and peak amplitude of 1000 nm for all images with a resolution of 512 × 512 pixels per image in the dimension of 5 μm × 5 μm. The samples were measured at a temperature of 25 ± 1°C with peak force ™ QNM™ (Quantitative Nano Mechanics) software mode .
Confocal laser scanning microscopy (CLSM) study
Drug/dye permeation mechanism in the rat skin including the depth of penetration of ethosomes and conventional liposomes loaded with 6-coumarin dye were studied by CLSM. Dye loaded samples were subjected to 8 h treatment with the rat skin samples fitted in the Franz diffusion cell with the SC upside. The fluorescent loaded formulations were placed on the donor membrane and after 8 h the skin was washed thoroughly with ultra-pure water. For the comparison purpose, hydroethanolic solution with 6-curmarin dye was also studied. The treated skins samples were cut vertically at the length of 5-10 µm thickness, placed on the glass slide with help of transparent adhesive. Particles penetration through the different layers of the skin was visualized through Z-axis by Confocal microscope (Leica TCS SPE, Germany). An argon (AR) beam of green filter with emission at 502 nm and excitation at 488 nm was used for image formation (Zhang et al., 2010) . The depth of penetration and relative fluorescence of the 6-coumarin dye in skin layer were analysed by Leica LAS SF software. The result of CLSM was represented in Airy unit (AU) and calculated by the depth of penetration based on the excitation and emission at respective wavelengths. 
Physical stability study
The optimised formulation of ethosomes was subjected to the physical stability study for the period of 3 months at 2-4°C. The size and zeta-potential were measured every 30 days over a period of 3 months. Any change in the size and charge was considered as a change in stability profile of the formulation. The data were shown as mean ± SD (n = 3).
Gel preparation and evaluation of its rheology
For in-vivo animal studies, optimised formulation of ethosome (RES-1), conventional liposomes and hydro-ethanolic solution were incorporated separately into a gel of 0.5% carbopol. Triethanolamine (TEA) was used to maintain the pH (pH 5) of the gel and to impart viscosity. The rheological properties of the final gel formulation formulations were measured by Haake MARS Rheometer (Germany). Data analysis was performed using Haake MARS RheoWin 3 software. The spindle selected for all the experiments was CP Cone C60/1°Ti, D = 60 mm diameter with plate MP-C60. The rheometer instrument was equipped with a universal temperature controller (Thermal Analysis, Germany) to maintain the base plate temperature at 32 ± 0.1°C during the analysis. The formulations were characterised by flow behaviour, thixotropy and oscillation frequency (Żyła et al., 2013) .
In-vivo pharmacokinetic studies
Comparative pharmacokinetic evaluations of transdermal formulations and an oral formulation were performed using Sprague-Dawley strain rats. A total no of 4 formulations were used for the study: RES-1 gel, conventional liposomes gel, hydroethanolic gel and an orally administered RXL tablet of equivalent dose. Rats of weight range of 150-180 g were supplied from the local supplier Sapphire Enterprise (Selangor, Malaysia). An institutional animal ethical committee approval from International Islamic University Malaysia [IIUM/IACUC Approval/2015/(5) (25)] was obtained before the study. Animals were kept in standard laboratory condition in 12 h light/dark cycle at 22 ± 1°C. Animals were supplied with a normal diet of pellets and water. Preparation of animals for the study required to shave the abdominal area for the application of the formulated gel. This was done carefully by electric clipper before the experiment. The rats and the shaved areas were observed for any kind of abnormality. A dose of equivalent amount of 6 mg RXL selected as transdermal and oral dose. The animals were dived into 4 groups; group 1, 2 and 3 received RES-1, conventional liposomes gel and hydroethanolic gel, respectively. Group 4 was administered with an oral suspension of RXL tablet Evista (Elly Lilly). After an acclimatisation, the rats were anaesthetized by an intravenous administration of a drug solution (a combination of ketamine and xylene).The blood samples were collected from retro-orbital sinus at different intervals of time (0, 2, 4, 6, 8, 12, 24, 48 h) in Eppendorf tubes containing EDTA-sodium as anti-coagulant. Immediately, the tubes were centrifuged (MIRKO 120, Hettich) at 4000 rpm for 15 min to separate plasma and stored at −80°C until further analysis by HPLC method. Pharmacokinetic parameters such as C max (the maximum plasma concentration) and T max (time to reach maximum plasma concentration) were obtained directly from plasma concentration versus time graph curve. The areas under the curves (AUC 0-48 and AUC 0-inf ) were calculated by trapezoid rule. Elimination rate constant (K el ) was calculated from the slope of the log plasma concentration versus time plot and elimination half-life (t 1/2 ) was calculated by formula t 1/ 2 = 0.693/Kel.
HPLC estimation of raloxifene in rat plasma
The HPLC system consisted Shimadzu LC-20ÂT low pressure gradient solvent delivery segment (Shimadzu, Kyoto, Japan) equipped with DGU-20-A512 degassing unit, SPD-M20A Prominence Diode array UV/VIS detector over a range of 190-800 nm, SIL-20AHT autosampler, CTO-10AS VP Column oven and LC workstation data processor. The chromatographic separation of RXL from the plasma was carried out on thermo-fisher syncronis RP-column C-18 (15 mm × 4.6 mm, 5 µm pore size) with a loop size of 20 µl. The sample was run for 15 min together with a mobile phase containing a mixture of phosphate buffer (pH 6.1) and acetonitrile (66:34, v/v) maintained at 30°C, flow rate of 1.0/min and U.V detection at 285 nm. Liquid/liquid extraction procedure was followed using ethyl acetate as the extracting solvent. An accurate quantity of 0.450 ml of rat plasma was taken in a glass tube. To this, 50 μl of IS (diclofenac sodium dissolved in methanol and water, concentration: 2 µg/ml) was added and mixed well. A volume of 4 ml ethyl acetate was mixed to the plasma and subjected to vortex mixing for 45 s followed by centrifugation for 25 mins at 4500 rpm. The supernatant organic layer was separated to a different test tube and slowly evaporated to complete dryness through a stream of nitrogen gas at the temperature below 50°C. The dried layer was reconstituted with 300 µl of acetonitrile, filtered with 0.22 µm membrane and the same was analysed by HPLC . Calibration range was 50 ng/ml to 2000 ng/ml.
Results and discussion
The concept behind the improved transdermal flux of ethosomes relies on the concentration of ethanol and its penetration enhancing ability by disrupting the stratum corneum (William and Barry, 2004) . Ethosomal vesicles consist of a high concentration of ethanol ranging from 15 to 45% and a biocompatible polymer like phospholipid. The penetration enhancing effects have been demonstrated by Kadir and group (1987) as push-pull mechanism (Kadir et al., 1987) . In our research, ethosomes were prepared by rotary evaporation method as this method has been reported to improve a higher entrapment efficiency and homogeneity of lipid vesicles (El Zaafarany et al., 2010; Fang et al., 2008) . The formulation compositions of ethosomes are shown in Table 1 . The selection of the optimised ethosomal formulation was done using primary screening parameters like vesicle size, EE% and flux obtained from the ex-vivo permeation study.
Vesicles size, PDI and surface charge
The particle sizes of ethosomes are shown in Table 2 . A total of five formulations were prepared with the variation in the ethanol concentration. A representative size distribution graph is given in Fig. 1 . The size of RES formulations decreased as the ethanol concentration increased from 20% to 40%. This is due to the increasing concentration of ethanol which makes the vesicular structures more flexible and leakier resulting in the disruption of the membrane lipid bilayer and reduction in particle size. However, the decrease in size was not significant except in RES-1 and RES-2 (p ≤ 0.01). The PDI data shows a polydisperse distribution of vesicle sizes with a narrow distribution. The sizes of RES vary due to the variation in the ethanol concentration as the amount of PC-90G and RXL were equal in all RES formulations (Abdel Messih et al., 2017) . The zeta potentials of the ethosomes were recorded positive (from +54.73 ± 0.05 to +36.93 ± 2.17) at a pH value of 5.05 ± 0.5. The charge on the phospholipid is neutral as the negative charge by phosphate and positive charge on amine group together results in net neutral charge at pH.7 (behaving as a zwitterion). During formation of ethosomal vesicles, the hydration was done by ethanol for uniformly deposited layer on the round bottom flask containing lipid loaded with raloxifene. The results of zeta-potential for ethosomes were found to be highly positive due to overall formulation compositions of ethosomes. When ethanol concentration was increased from 20% (RES-1) to 40% (RES-5), formulations showed a decrease in the zeta-potential. This indicates that zeta potential of the formulation is affected by alkyl group of ethanol.
Entrapment efficiency (EE%) and ex-vivo permeation
Quantification of the entrapped drug in the vesicular system is important as it affects drug delivery potential. The effect of matrix and concentration of ethanol can directly affect the EE% for ethosome formulations. The EE% of the developed formulations are given in Table 2 .
The EE % was found to be maximum for ER-1 (62.65 ± 0.63%) with 20% of ethanol (v/v) and minimum for ER-5 (11.74 ± 0.195) with 40% ethanol (v/v). These values are significantly different from each other (p ≤ 0.001). The decrease in EE % of ethosomes with the increase of ethanol concentration results from the fact that the lipid membrane becomes more fluidic and leaky, which makes it more permeable, making the vesicles distorted and decrease in EE% (Bhosale and Avachat, 2013) . The correlation between the EE% and ethanol results Pearson correlation values of r = −0.994, p = 0.001). The flux (J) pattern in ethosomes ranges from 22.14 ± 0.83 (µg/cm 2 /h) for 20% to 13.8 ± 1.43 (µg/cm 2 /h) for 40% ethanol ( Table 2 ). The flux of the ethosomal formulations were found to be depended on size as well as on ethanol content of the formulations. The Pearson correlation for transdermal flux when compared with the concentration of ethanol gives values of r = −0.644 and p = 0.24. Our results of ethosome formulations follow a decreasing pattern of EE% and size at higher concentration of ethanol and it does not show any agreement with the previous studies published (Ahmed et al., 2016; Bisht et al., 2017) . A complex relation among transdermal flux, ethanol concentration and vesicle size of the ethosomal formulations is shown in Fig. 2 40% v/v) . This relationship can be explained based on the higher solubilization of the lipid matrix at a higher concentration of ethanol that makes the lipid bilayer deteriorated and results in more leakage of the drug. The transdermal flux (J) for conventional liposomes and hydroethanolic formulations were found to be 28 ± 0.14 (µg/cm 2 /h) and 1.02 ± 0.24 (µg/cm 2 /h), respectively. Overall the permeation of ethosomes was higher as compared to liposomes and hydroethanolic solution with an enhancement ratio (ER) of 17.22 and 21.6 fold, respectively. Ethanol itself is known for its transdermal penetration enhancement effect (Magnusson et al., 1997) . The presence of ethanol in ethosomes imparts them with flexibility and it affects the intercellular region of the SC. It relates to pull and push effects of particles in the SC. The push effect is a thermodynamic activity due to evaporation of ethanol and the pull effect is due to reduction in barrier property of SC by ethanol. Both of these effects result in penetration enhancement of the drug molecule (Dubey et al., 2007 , Kadir et al., 1987 . Additionally, ethanol causes lipid extraction and osmotic expansion which affect drug permeation through the SC (Krill et al., 1992; William and Barry, 2004) . However, it is already established that rat abdominal skin does not have the same permeability properties as the human skin and that the 21.6-fold flux increase may not be observed with human skin. In addition, the pig ear skin has been shown to be closer to human skin in transdermal drug delivery studies. However, based on results of vesicles size, S. Mahmood et al. International Journal of Pharmaceutics 542 (2018) 36-46 PDI, surface charge, EE% and transdermal flux (J), RES-1 was selected as the optimized formulation and explored for further evaluation.
Complexation study via ATR
Infrared studies confirmed the complexation behaviour between PC-90G and drug. In the ATR scan of raloxifene HCl, CeH stretching was found at 3126 cm −1 and other characteristics peaks were found below 1700 cm −1 . In the case of PC-90G, the CeH stretching was observed at 
DSC study
The DSC study was carried out to check the presence of any crystallinity of RXL in the formulation and to find out the difference in melting points of vesicular structures of ethosomes with liposome and PC-90G. The transition temperature (T g ) of PC-90G was observed at 47.22°C (Fig. 4) . The DSC thermogram of the conventional liposome containing PC and raloxifene showed a transition peak at 55.39 ± 0.44°C. In the case of ethosomes, the presence of ethanol makes it more fluidic in nature than conventional liposome and transfersomes, and the transition was observed at -14.52 ± 0.55°C (Fig. 4) and the same was in agreement with the previous report published by Touitou et al. (2000) . To study further the physical state (crystallinity) of raloxifene in the vesicular structures freeze-dried formulations namely liposomes, ethosomes and a physical mixture of PC-90G and RXL were scanned. The melting temperature (T m ) of raloxifene was recorded at 271.32°C, however the peak of RXL disappeared in the case of ethosomes. The shifting or disappearance of raloxifene indicates an amorphous state of the drug in the formulation (Lim et al., 2017) .
XRD study
The XRD graphs of RXL, PC-90G, RES-1 formulation and a mixture of RXL and PC-90G are shown in Fig. 5 . The observed XRD pattern of raloxifene is characterised by many crystalline peaks as shown WAXS (Dudhipala and Veerabrahma, 2016) . RXL showed many sharp, narrow and intense peaks, claiming its high crystallinity at 2θ scattered angles 6.7, 9.5, 13.4, 14.3, 15.7, 19.0, 20.9, 21.3, 22.4, 22.6, 24.4, and 29.8 . However, in the non-crystalline state, the pattern observed in the optimised ethosome formulation was different from that of RXL alone. The peaks in optimised formulations were diminished or suppressed and not observed in case of ethosomal preparations. Many researchers have also reported the similar results in which the peak intensity decreases and the confirmation of the amorphous state are confirmed (Vidyasagar and Naik, 2016) .
Morphology, size and topology of ethosome vesicles
FESEM was used to investigate the morphology of the vesicular structures as it provides a much clear image with a 3D-view. A clear multilamellar vesicular structure was observed for ethosomal formulation (Fig. 6A) . To further confirm the size and bilayer formation of the optimised RES-1, HRTEM scanning was performed at negative staining mode. The micrograph of the optimised formulation (RES-1) is shown in (Fig. 6B) ; the vesicles were found to be round and spherical, however they were deformed because of ethanol (Chen et al., 2017) . AFM clearly shows the particles topology in the form of 3-D and 2-D images, the step graphs and particle size graphs also give information about the particle size. The obtained 2-D images related to the particles length and 3-D image (Fig. 6C) show that the particles are uniformly distributed. A detailed study regarding these observations has already been published by our group .
CLSM study
The CLSM assessment was observed to compare the penetration ability of the ethosome formulation (RES-1) over conventional Fig. 3 . ATR spectrums for drug-PC 90G interaction study of ethosomes formulations. Fig. 4 . The thermograms of A. RXL, B. RES-1 and C. PC-90G. In RES-1 no RXL peak was observed and a transition at −14.52 ± 0.55°C was recorded. S. Mahmood et al. International Journal of Pharmaceutics 542 (2018) 36-46 liposomes and hydroethanolic drug solution. Coumarin-6 dye was entrapped within the vesicles and they were subjected to ex-vivo skin permeation study. The attachment of the fluorescent probe in the skin components signifies the depth and distribution of the dye via the carrier. For calculation, airy unit (AU) was used and it is theoretically equivalent to the diameter of a pinhole and in our case 1 AU was equivalent to 61.24 µm. It is shown in Fig. 7 that vesicles of the RES1formulation were evenly distributed through the skin when compared with liposomes. The mechanism of delivering fluorescent dye for ethosomal vesicles can be understood by ethanol effect as it acts as a penetration enhancer and directly affects the intercellular region of SC (Komatsu and Okada, 1996) . The AU and maximum fluorescence (Max FL) for RES-1 was calculated as 24.94 and 7.82, respectively. Max FL is the maximum light emitted from the sample. However, the hydroethanolic solution showed a higher value of Max FL i.e 83.24 and AU value of 22.18 (Dubey et al., 2007) . The liposomes formulation showed the least penetration, both with respect to depth (AU of 9.62) and intensity Max FL (4.47) due to its rigid structure when compared to RES-1. Similar findings were reported and also justified by many other researchers (Subongkot et al., 2013; Touitou et al., 2000) .
31 P-NMR spectroscopy
The 31 P NMR study was performed to evaluate the configuration of phospholipid in bilayer and to further confirm the bilayer of lipid vesicles including the mobility of the phosphate moiety of the lipid head group and provide an idea of any aggregates.
31 P-NMR spectra of all the samples are shown in Fig. 8 . After fixing the H 3 PO 4 at 0 ppm, the blank PC-90G prepared in the form of bilayer showed a single sharp peak, which shows a spectrum configuration of small, unilamellar vesicles (Cullis and De Kruijff, 1979) . The addition of raloxifene HCl in PC-90G at the time of formation of the bilayer resulted in a shifting in the peak S. Mahmood et al. International Journal of Pharmaceutics 542 (2018) 36-46 due the downfield (deshielding) of PC-90G, as compared to PC-90G alone. This indicates the increased exposure of phosphate head group of PC-90G at the surface of its membranes. This downfield resonance (deshielding) after addition of raloxifene was an outcome of additional aromatic rings of raloxifene which makes them deshielded and oriented themselves in the lipid bilayers in the proximity of the phosphate head groups. Deshielding and shielding effects are affected by the concentration of raloxifene as in all the formulation the concentration was unchanged (Leenstra and Amicangelo, 1998) . For ethosomes containing 20% ethanol, PC-90G and RXL, the shielding effect was more than the PC-90G +RXL. The mobility of polar headgroups, due to the presence of ethanol in ethosomes is higher than the other formulations which make them highly shielded and shifts the shoulder to low-field from H 3 PO 4 (Dufourc et al., 1992; Touitou et al., 2000) . Ethanol contains an alkyl group which is electron donating and imparts a positive charge to formulation (ethosomes). Ethosomes show the presence of large unilamellar vesicles systems as the peaks were very narrow with sharp spectral lines. They also show bilayer powder pattern, which indicates the rapid chemical shift anisotropic motion. In all the vesicles we observed Lorentzian lineshapes which indicate that the particles sizes are small; these sizes are proportional to the line width (De Kruijff et al., 1976; Fenske, 1993; Touitou et al., 2000) .
Physical stability study
Physical stability of RES-1 was tested until 90 days after recording changes in particle size, size distribution (PDI) and zeta-potential. The results are shown in Table 3 . The change in recorded parameters were significant ((P ≤ 0.002) for ethosomes at 90th day. The PDI data (not shown) were also below 0.3 that indicates that particle size distribution remained unchanged throughout the stability periods. The zeta-potential of all the formulations showed stable behaviour upto 90 days. The particle size of the formulations increased with time due to the possibility of fusion of the ethosomal vesicles (Yan et al., 2016) .
Rheology of formulated gel
For the purpose of the in-vivo study, gel system was formulated for RES-1, conventional liposomes and hydroethanolic solution. The pH of the formulated gel was maintained within a range of 5.5-6.0 using TEA. All the formulations showed a pseudoplastic behaviour (Fig. 9 A) . Yield stress and thixotropy areas (determined by controlled rate step) of the formulated gels are shown in Fig. 9B and Table 4 . Yield stress is the minimum stress that must be applied on a material to make it start flowing (Gargallo and Radic, 2009) . To determine the nature of gels, frequency sweep test was performed in which G' (elastic) was higher than G'' (viscous/Loss modulus), that shows an elastic nature of the formulated gel. The values of tanδ for all the gel formulations were below 45° (Fig. 8C ) which indicate that gels possessed viscoelastic properties when subjected to deformation (Fagir et al., 2015) .
Pharmacokinetic studies
To assess the pharmacokinetic parameters of RXL from the tested formulations, a non-compartmental model was applied and the following parameters were recorded like C max , T max , AUC 0-48 , AUC 0-inf , K el and t 1/2. The pharmacokinetic parameters of all the formulations are provided in Table 5 and the corresponding plasma concentration versus time curves are illustrated in Fig. 10 . The C max for the formulations RES-1(ethosomes) after the application was found to be 171.16 ± 47.02 ngml −1 and T max was 8.00 ± 2.52 h, respectively. On the other hand, the oral suspension of the marketed formulation showed a C max and T max values 140.14 ± 23.18 ng and 5.33 ± 2.30 h, respectively. The difference between C max and T max values between RES-1 and oral suspension were found to be significant (P ≤ 0.05). Higher T max after transdermal application results from the barrier property of the skin (stratum corneum) as well as the sustained-release of RXL from the gel formulation as compared to oral suspension. The AUC 0-48 and AUC 0-∞ of the RES-1 gel were found to be 4473.73 ± 579.87 ng.h/ml and 7946.15 ± 1667.10 ng.h/ml. For oral suspension of RXL, the AUC 0-48 and AUC 0-∞ were found to be (2841.18 ± 1019.92 ng.h/ml and 4045.95 ± 2290.42 ng.h/ml); these values were significantly (p ≤ 0.05) lower than that of the ethosome formulation. The increase in AUC achieved in ethosomes formulation could be due to the maintenance of the concentration of drug within the pharmacologically effective range for a longer time period. The significant (p ≤ 0.05) high AUC 0-48 value of ethosome formulation as compared to other formulations indicates higher bioavailability for RXL when administered through transdermal delivery route as compared with the marketed oral suspension. This higher bioavailability is due to the loading of RXL into the transdermal formulation of ethosome which helped in by passing the extensive hepatic metabolism by avoiding G.I.T when administered through the transdermal system in return providing high systemic circulation (Fagir et al., 2015; Morsi et al., 2017) . The t 1/2 of formulation RES-1 (35.33 ± 14.59 h) was 158% higher (p ≤ 0.05) than that of oral formulation (22.29 ± 9.50 h). The higher t 1/2 of ethosome formulation may due to the longer absorption when delivered through the transdermal system. The higher bioavailability (expressed in mean, n = 6) of the optimised formulation used in pharmacokinetic studies was assessed by AUC 0-48 . The relative bioavailability was calculated as AUC 0-48 ethosomes/AUC 0-48 oral for ethosome formulation; AUC 0-48 ethosomes/AUC 0-48 conventional liposomes for liposomes; and AUC 0-48 ethosomes/AUC 0-48 hydroethanolic gel for hydroethanolic gel formulation. The relative bioavailability was found to be 157% for RES-1, 215% for liposomes and 212% for hydroethanolic gel. Our results were in agreement with other reported articles (Nekkanti et al., 2013; Ravi et al., 2014; Velpula et al., 2013) . The higher bioavailability achieved by these transdermal carriers prove the efficiency of these delivery systems for poorly soluble drugs like raloxifene. In all pharmacokinetic parameters, the liposomes and hydro-ethanolic formulations were found to be significant lesser Table 3 Stability study of RES-1 formulation using size and zeta-potential.
RES-1 formulation Size (nm) zeta-potential (mV) 0 day 150.7 ± 0.25 +54.7 ± 0.05 30th day 149.8 ± 1.6 +56.1 ± 1.24 60th day 151.5 ± 1.77 +44.5 ± 0.60 90th day 184.2 ± 3.15 +49 ± 1.15
(p ≤ 0.001) as compared to RES-1. As a result, it could be concluded that liposomes and hydro-ethanolic formulations of raloxifene are not fit for the transdermal application of RXL.
Conclusion
The objective of this research was to develop RXL loaded ethosomes formulation that can overcome the low bioavailability issue of the drug. Prepared formulation of ethosomes showed a better entrapment and permeation through ex-vivo studies. Advanced characterization parameters were performed to establish the fate of ethosomal vesicles together with the entrapped drug. AFM, HRTEM, XRD and 31 P NMR studies showed that the ethosome formulation was well defined by its size, shape and its bilayer formation. In-vivo pharmacokinetics revealed that ethosomal formulation can deliver and maintain the concentration of RXL, which is much higher when compared with the oral formulation and other transdermal formulation (liposomal gel and hydroethanolic gel). Therefore, these findings suggest that ethosomal carrier can be successfully exploited for bioavailability enhancement of RXL. Table 5 In-vivo pharmacokinetic parameters of RXL loaded gel formulations RES-1, conventional liposomes, hydroethanolic solution and oral suspension, (mean ± SD, n = 6).
Formulation code C max (ng/ml) T max (h) AUC 0-48 (ng/ml/h) AUC 0-inf (ng/ml/h) Kel Half-life(t 1/2 ) (h) 
